Therapeutic

Vaccine combinations against bladder cancer: IO Biotech

Vaccine combinations against bladder cancer: IO Biotech

In July 2023 IO Biotech announced that the University of California Davis Comprehensive Cancer Centre has dosed the first patient in an investigator-initiated trial of IO102-IO103. IO Biotech uses its T-win technology platform to develop novel, immune-modulating...

Targeting inflamed brain cells to reduce Alzheimer’s

Targeting inflamed brain cells to reduce Alzheimer’s

A team from Japan’s Juntendo University suggest that their latest vaccine, “SAGP”, may revolutionise treatment of Alzheimer’s disease. Presenting at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions 2023, the researchers hope to...

Merck and Moderna begin Phase III melanoma trial

Merck and Moderna begin Phase III melanoma trial

In July 2023 Merck and Moderna announced the initiation of a Phase III clinical trial evaluating V940 (mRNA-4157), an investigational individualised neoantigen therapy (INT), in combination with KEYTRUDA in patients with resected high-risk melanoma. Recruitment for...

Continued progress for Vaxxinity against Parkinson’s

Continued progress for Vaxxinity against Parkinson’s

Less than a month since we reported Vaxxinity’s “promising” results in a trial of UB-312, the company has released further encouraging news; new data demonstrates that UB-312 has established “clear target engagement” by slowing seeding of alpha-synuclein (αSyn) in...

Vaccines are the “future” in cancer, says Dr Pravin Kaumaya

Vaccines are the “future” in cancer, says Dr Pravin Kaumaya

During the Congress in April we were pleased to meet Dr Pravin Kaumaya for a conversation about the state of play in the cancer vaccine field. Dr Kaumaya joined us to chair the Cancer and Immunotherapy track, present a session and join a panel. Here we learn more...

UK government and BioNTech join forces on cancer trials

UK government and BioNTech join forces on cancer trials

Following the signing of a memorandum of understanding between the UK government and BioNTech in January 2023, an agreement has been established to provide cancer patients with “improved access” to cancer trials. The partnership will ensure that more patients are able...

Vaxxinity announces positive Parkinson’s trial results

Vaxxinity announces positive Parkinson’s trial results

In June 2023 Vaxxinity announced positive results from Part B of the Phase I clinical trial of UB-312, an investigational vaccine for Parkinson’s disease. The results show that the vaccine was well tolerated and induced anti-alpha-synuclein (aSyn) antibody responses...